WHAT IS CLAIMED IS:

1. A compound of Formula I



I

or a pharmaceutically acceptable salt thereof, wherein:

X is $-CO_2H$, 1*H*-tetrazol-5-yl or 2*H*-tetrazol-5-yl;

each R^a may be substituted at any substitutable position on A and each R^a is independently selected from the group consisting of: fluoro, chloro, bromo, NH_2, methyl, ethyl, methoxy and CF_3;

R^1 and R^2 are each independently selected from the group consisting of: C_{1-6}alkyl and C_{3-6}cycloalkyl; and

A is selected from the group consisting of:

<table>
<tr><td>1)
  </td><td>2)
  </td><td>3)
  </td></tr>
<tr><td>4)
  </td><td>5)
  </td><td>6)
  </td></tr>
</table>

7) 	8) 	9) 
10) 	11) 	12) 
13) 	14) 	15) 
16) 	17) 	18) 
19) 	20) 	21) 
22) 	23) 	24) 

25) 	26) 	27) 
28) 	29) 	30) 
31) 	32) 	33) 
34) 	35) 	36) 
37)  and	38) 	

wherein for 38) above R^a is substituted on **A** as shown and **Z** is selected from the group consisting of: phenyl, benzimidazolyl, benzofuranyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl,

naphthyridinyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidinyl, methylenedioxybenzoyl, tetrahydrofuranyl, and tetrahydrothienyl.

2. The compound according to Claim 1 wherein R^1 and R^2 are each C_{1-4}alkyl.

3. The compound according to Claim 1 wherein X is $-CO_2H$.

4. The compound according to Claim 1 wherein X is 1*H*-tetrazol-5-yl or 2*H*-tetrazol-5-yl.

5. The compound according to Claim 1 wherein A is



6. The compound according to Claim 5 wherein no R^a group is present.

7. The compound according to Claim 5 wherein R^1 and R^2 are each C_{1-4}alkyl.

8. The compound according to Claim 1 wherein A is



9. The compound according to Claim 8 wherein no R^a group is present.

10. The compound according to Claim 8 wherein R^1 and R^2 are each C_{1-4}alkyl.

11. The compound according to Claim 1 wherein A is



and wherein the two additional R^a groups may be substituted at any substitutable position on A above.

12. The compound according to Claim 11 wherein no R^a group is present.

13. The compound according to Claim 11 wherein R^1 and R^2 are each C_{1-4}alkyl.

14. The compound according to Claim 1 wherein A is



15. The compound according to Claim 14 wherein R^1 and R^2 are each C_{1-4}alkyl.

16. A compound selected from the following group:





and

or a pharmaceutically acceptable salt of any of the above.

17. The compound according to Claim 1 wherein R^1 and R^2 are each methyl.

18. The compound according to Claim 1 wherein R^1 is methyl and R^2 is ethyl.

19. A pharmaceutical composition comprising a compound according to Claim 1 in combination with a pharmaceutically acceptable carrier.

20. A method for preventing, delaying or reversing the progression of Alzheimer's Disease in a patient in need thereof comprising administering to said patient a compound according to Claim 1 in amount that is effective for preventing, delaying or reversing the progression of Alzheimer's Disease.

21. A method for treating Alzheimer's Disease in a patient in need thereof comprising administering to said patient a compound according to Claim 1 in amount that is effective for treating Alzheimer's Disease.

22. A compound according to Claim 1 of Formula I'



I'

or a pharmaceutically acceptable salt thereof, wherein:

Z is selected from the group consisting of: phenyl, benzimidazolyl, benzofuranyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthyridinyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidinyl, methylenedioxybenzoyl, tetrahydrofuranyl, and tetrahydrothienyl,

X is $-CO_2H$, 1*H*-tetrazol-5-yl or 2*H*-tetrazol-5-yl,

R^1 and R^2 are each independently ethyl or methyl, and

each R^a is independently selected from the group consisting of: fluoro, chloro, bromo, NH_2, methyl, ethyl, methoxy and CF_3:

23. The compound according to Claim 22 wherein **Z** is phenyl.

24. The compound according to Claim 22 wherein R^a is not present.

25. The compound according to Claim 22 wherein R^1 and R^2 are each methyl.

26. The compound according to Claim 22 wherein X is $-CO_2H$.

27. The compound according to Claim 22 wherein X is 1*H*-tetrazol-5-yl or 2*H*-tetrazol-5-yl.

28. The compound according to Claim 22 wherein R^a is selected from the group consisting of: fluoro, chloro and bromo.

29. The compound according to Claim 22 of Formula I'a



I'a

or a pharmaceutically acceptable salt thereof, wherein:

X is $-CO_2H$, 1*H*-tetrazol-5-yl or 2*H*-tetrazol-5-yl and

R^1 and R^2 are each independently ethyl or methyl.

30. A pharmaceutical composition comprising a compound according to Claim 22 in combination with a pharmaceutically acceptable carrier.

31. A method for preventing, delaying or reversing the progression of Alzheimer's Disease in a patient in need thereof comprising administering to the patient a compound according to Claim 22 in amount that is effective for preventing, delaying or reversing the progression of Alzheimer's Disease.

32. A method for treating Alzheimer's Disease in a patient in need thereof comprising administering to said patient a compound according to Claim 22 in amount that is effective for treating Alzheimer's Disease.